Hiporfin photodynamic therapy for early-stage cervical cancer: A case report
A 28-year-old female patient, diagnosed with stage IA1 cervical cancer, received PDT treatment with intravenous injection of Hiporfin, a HpD type photosensitizer. The patient's human papillomavirus (HPV) and cytology testing results were negative at the 3-month. At 6 months, the lesions on the cervical surface and within the cervical canal had completely resolved. There were no signs of recurrence or HPV infection during the 12-month follow-up period. There were no serious adverse events reported during or after the PDT treatment.
Authors
- Lihui Wei (ORCID: https://orcid.org/0000-0002-2478-8790)
- Mingmei Li (ORCID: https://orcid.org/0000-0002-5097-2882)
- Changzhong Li (ORCID: https://orcid.org/0000-0001-5654-1031)
- Yu Liu (ORCID: https://orcid.org/0009-0001-9401-2330)
- Hao Li (ORCID: https://orcid.org/0000-0001-5516-6313)
- Ruifang Wu (ORCID: https://orcid.org/0000-0002-4231-0774)
- Ruizhen Li (ORCID: https://orcid.org/0009-0005-6621-839X)
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
- Peking University Shenzhen Hospital (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
Publication Details
- Journal
- Photodiagnosis and Photodynamic Therapy
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1016/j.pdpdt.2024.104422
- Citations
- 1
- Primary Topic
- Photodynamic Therapy Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.42